Literature DB >> 18607923

Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients.

Renske J Scheenstra1, Evert Rijntjes, Dénes L J Tavy, Herman Kingma, Harry G M Heijerman.   

Abstract

CONCLUSION: The reported prevalence of vestibulotoxicity (30.4%) in cystic fibrosis (CF) patients supports vestibulotoxicity screening in CF patients during or after tobramycin exposure. Prospective longitudinal investigation is required for a more specific evidence-based proposal.
OBJECTIVE: To investigate the prevalence of tobramycin-induced vestibulotoxicity in CF patients, as it had not been investigated before. PATIENTS AND METHODS: In this observational cohort study, 23 CF patient volunteers from the Haga Teaching Hospital Adult CF centre who had been exposed to at least one treatment with systemically administered tobramycin were included. Subjective feelings of dizziness were measured using validated questionnaires and vestibular symptoms were assessed by physical examination. Electronystagmography (ENG) with caloric irrigation was used as the gold standard.
RESULTS: Peripheral vestibular loss was found in seven patients (7/23 = 30.4%). Central vestibular loss was found in one patient. Analysis of the 19 completed questionnaires showed that 12 patients (12/19 = 63.2%) did not experience dizziness and 3 patients (3/19 = 15/8%) experienced specific vestibular symptoms. The results of the questionnaire could not predict the results of ENG with caloric irrigation. Physical examination showed no abnormalities in any patients. No age- or dose-related predictive factors were found.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18607923     DOI: 10.1080/00016480801968534

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  5 in total

1.  Changes in the inner ear structures in cystic fibrosis patients.

Authors:  Henrique F Pauna; Rafael C Monsanto; Natsuko Kurata; Michael M Paparella; Sebahattin Cureoglu
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2016-11-16       Impact factor: 1.675

Review 2.  Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.

Authors:  Andrew Prayle; Alan Watson; Heather Fortnum; Alan Smyth
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

3.  Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort.

Authors:  Chelsea M Blankenship; Lisa L Hunter; M Patrick Feeney; Madison Cox; Lindsey Bittinger; Angela C Garinis; Li Lin; Gary McPhail; John P Clancy
Journal:  Am J Audiol       Date:  2021-01-19       Impact factor: 1.636

4.  ASK1 is a novel molecular target for preventing aminoglycoside-induced hair cell death.

Authors:  Jacqueline M Ogier; Yujing Gao; Eileen M Dunne; Michael A Wilson; Sarath C Ranganathan; Gregory H Tesch; David J Nikolic Paterson; Alain Dabdoub; Rachel A Burt; Bryony A Nayagam; Paul J Lockhart
Journal:  J Mol Med (Berl)       Date:  2022-04-26       Impact factor: 5.606

5.  Tobramycin and vestibulotoxicity: retrospective analysis of four cases.

Authors:  S E M Vonk; E J M Weersink; C J Majoor; E M Kemper
Journal:  Eur J Hosp Pharm       Date:  2021-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.